“Doctors don’t want pharma reps to buy them dinner, right? They don’t. They want help in the five minutes that really matter,” Viz.ai’s CEO Chris Mansi and Salesforce’s Frank Defesche explain in this Vanguards of Health Care podcast episode. Mansi and Defesche sit down with Bloomberg Intelligence analyst Matt Henriksson to talk about Viz.ai and its agentic AI platform that connects medical scans and images to the right diagnosis and treatment guidelines. Also tune in to learn how the Viz.ai platform aims to partner with Salesforce’s life-science division to improve pharmaceutical point-of-care workflow while providing more personalized care.

&ldquo;Doctors don&rsquo;t want pharma reps to buy them dinner, right? They don&rsquo;t. They want help in the five minutes that really matter,&rdquo; Viz.ai&rsquo;s CEO Chris Mansi and Salesforce&rsquo;s Frank Defesche explain in this Vanguards of Health Care podcast episode. Mansi and Defesche sit down with Bloomberg Intelligence analyst Matt Henriksson to talk about Viz.ai and its agentic AI platform that connects medical scans and images to the right diagnosis and treatment guidelines. Also tune in to learn how the Viz.ai platform aims to partner with Salesforce&rsquo;s life-science division to improve pharmaceutical point-of-care workflow while providing more personalized care.

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Healthcare by Bloomberg Intelligence

Viz.ai Taps Artificial Intelligence to Accelerate Point-of-Care Decisions 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/f8c55d70-79f7-48a9-b288-b36300c66cd1/transcript

“Forty percent of patients in this country alone in the first year drop out [of current retinal disease treatments] and every one of those patients ends up going blind. By far the most expensive disease in the world is blindness and the reason for that is really quite simple. It’s because the mortality doesn’t change, the use of resources skyrockets, but the mortality doesn’t change. In this country, every blind patient costs over $66,000 a year,” says Pravin Dugel, CEO of Ocular Therapeutix. “If we reduce that dropout rate by even 10% with Axpaxli, and I’m sure we’ll do even better, we’re talking about a quarter million fewer patients in this country alone who will not go blind. The impact of that, not just on a human basis but on an economic basis, is astronomical.” In this episode of the Vanguards of Healthcare podcast, Pravin sits down with Bloomberg Intelligence senior analyst Ann-Hunter van Kirk to discuss how the company can reduce the therapeutic and economic burden of retinal diseases.

&ldquo;Forty percent of patients in this country alone in the first year drop out [of current retinal disease treatments] and every one of those patients ends up going blind. By far the most expensive disease in the world is blindness and the reason for that is really quite simple. It&rsquo;s because the mortality doesn&rsquo;t change, the use of resources skyrockets, but the mortality doesn&rsquo;t change. In this country, every blind patient costs over $66,000 a year,&rdquo; says Pravin Dugel, CEO of Ocular Therapeutix. &ldquo;If we reduce that dropout rate by even 10% with Axpaxli, and I&rsquo;m sure we&rsquo;ll do even better, we&rsquo;re talking about a quarter million fewer patients in this country alone who will not go blind. The impact of that, not just on a human basis but on an economic basis, is astronomical.&rdquo; In this episode of the Vanguards of Healthcare podcast, Pravin sits down with Bloomberg Intelligence senior analyst Ann-Hunter van Kirk to discuss how the company can reduce the therapeutic and economic burden of retinal diseases.

Ocular Therapeutix Cuts Blindness Toll

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/4331a593-4e34-4348-9d55-b45800bff63a/transcript

“We’re seeing it already to much more of a preventative proactive monitoring to find these things earlier in the patient journeys and help eliminate and prevent and reduce downstream costs,” IRhythm Technologies CEO Quentin Blackford discusses the opportunities of remote monitoring with Bloomberg Intelligence. In this Vanguards of Healthcare podcast episode, Blackford sits down with BI analyst Matt Henriksson for an in-depth interview on iRhythm, how its Zio monitoring platform provides an end-to-end solution to monitor patients without disrupting their everyday lives, and its strategy to expand into the primary care setting to provide a more proactive approach to detect cardiac arrhythmias and other health signals.

Listen to this episode on Apple Podcasts and Spotify.

&ldquo;We&rsquo;re seeing it already to much more of a preventative proactive monitoring to find these things earlier in the patient journeys and help eliminate and prevent and reduce downstream costs,&rdquo; IRhythm Technologies CEO Quentin Blackford discusses the opportunities of remote monitoring with Bloomberg Intelligence. In this Vanguards of Healthcare podcast episode, Blackford sits down with BI analyst Matt Henriksson for an in-depth interview on iRhythm, how its Zio monitoring platform provides an end-to-end solution to monitor patients without disrupting their everyday lives, and its strategy to expand into the primary care setting to provide a more proactive approach to detect cardiac arrhythmias and other health signals.
Listen to this episode on Apple Podcasts and Spotify.

IRhythm Pushes a Proactive Approach to Monitoring

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/7a327caf-80db-4bc1-bda7-b45100b4f237/transcript

Based on long-term results, “the effectiveness of that nanosecond pulse electric field begins to look as if it is a step function ahead of first generation PFA,”  Pulse Biosciences CEO Paul LaViolette says, referring to the next stage of pulsed-field ablation innovation. In this Vanguards of Healthcare episode, LaViolette sits down with BI analyst Matt Henriksson for an in-depth interview about the potential benefits of nanosecond ablation technology to treat atrial fibrillation, which combines an ultrashort pulse duration with a high amplitude of voltage. LaViolette also discusses the commercial strategy behind the launch of its NANOPULSE-AF IDE pivotal study, following promising first-in-human trial results.

Based on long-term results, &ldquo;the effectiveness of that nanosecond pulse electric field begins to look as if it is a step function ahead of first generation PFA,&rdquo; &nbsp;Pulse Biosciences CEO Paul LaViolette says, referring to the next stage of pulsed-field ablation innovation. In this Vanguards of Healthcare episode, LaViolette sits down with BI analyst Matt Henriksson for an in-depth interview about the potential benefits of nanosecond ablation technology to treat atrial fibrillation, which combines an ultrashort pulse duration with a high amplitude of voltage. LaViolette also discusses the commercial strategy behind the launch of its NANOPULSE-AF IDE pivotal study, following promising first-in-human trial results.

Pulse Biosciences Brings Differentiated Nanosecond Technology to PFA

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/f2af8770-3249-48bc-add8-b44a00d2b005/transcript

Viz.ai Taps Artificial Intelligence to Accelerate Point-of-Care Decisions

In 1 playlist(s)

Vanguards of Healthcare by Bloomberg Intelligence

Social links

Follow podcast

Recent clips